Stock of the Day

Madrigal Pharmaceuticals (MDGL)

$280.75

+$6.65 (+2.4%)

Market Cap: $6.25B

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.

The company is headquartered in West Conshohocken, Pennsylvania.

Recent News

• Madrigal Pharmaceuticals to Present at 46th Annual Goldman Sachs Health Care Conference (msn.com)
• Madrigal Pharmaceuticals to Participate in the 46th Annual Global Goldman Sachs Health Care Conference (globenewswire.com)